Estimating drug effects in the presence of placebo response: Causal inference using growth mixture modeling

Statistics in Medicine

Volumn 28, Issue 27, 2009, Pages 3363-3385

  Muthén, Bengt ^a   Brown, Hendricks C ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF MIAMI   (United States)

Author keywords

Latent classes; Potential outcomes; Principal stratification; Trajectory types

Indexed keywords

FLUOXETINE; IMIPRAMINE; PLACEBO;

ARTICLE; CAUSAL MODELING; CLINICAL TRIAL; DEPRESSION; DRUG EFFICACY; DRUG RESPONSE; GROWTH MIXTURE MODELING; HAMILTON SCALE; HUMAN; MAXIMUM LIKELIHOOD METHOD; MONTE CARLO METHOD; PLACEBO EFFECT; PROBABILITY; RESPONSE VARIABLE; STATISTICAL ANALYSIS; STATISTICAL MODEL; STATISTICAL SIGNIFICANCE;

ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; COMPUTER SIMULATION; DEPRESSION; HUMANS; MODELS, STATISTICAL; MONTE CARLO METHOD; PLACEBO EFFECT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA;

EID: 70449359832     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.3721     Document Type: Article

References (30)

1. McGrath P, Stewart JW, Janal MN, Petkova E, Quitkin FM, Klein DF. A placebo-controlled study of fluoxetine versus imipramine in the acute treatment of atypical depression. American Journal of Psychiatry 2000; 157: 344-350. (Pubitemid 30145918)
2. Montgomery SS. Clinically relevant effect sizes in depression. European Neuropsychopharmacology 1994; 4: 283-284.
3. Hedeker D, Gibbons RD. Longitudinal Data Analysis. Wiley: New York, 2006.
4. Angrist JD, Imbens GW, Rubin DB. Identification of causal effects using instrumental variables. Journal of the American Statistical Association 1996; 91:444-445.
5. Holland P. Causal inference, path analysis, and recursive structural equations models. In Sociological Methodology, Clogg C (ed.). American Sociological Association: Washington, DC, 1988; 449-493.
6. Rubin DB. Estimating causal effects of treatments in randomized and nonrandomized studies. Journal of Educational Psychology 1974; 66:688-701.
7. Rubin DB. Bayesian inference for causal effects. The Annuals of Statistics 1978; 6:34-58.
8. Frangakis CE, Rubin DB. Principal stratification in causal inference. Biometrics 2002; 58:21-29.
9. Little RJ, Yau LHY. Statistical techniques for analyzing data from prevention trials: treatment of no-shows using Rubin's causal model. Psychological Methods 1998; 3:147-159. (Pubitemid 128100918)
10. Gibbons RD, Hedeker D, Waternaux C, Davis JM. Random regression models: a comprehensive approach to the analysis of longitudinal psychiatric data. Psychopharmacology Bulletin 1988; 24:438-443. (Pubitemid 19031632)
11. Quitkin FM, Rabkin JG, Ross D, Stewart JW. Identification of true drug response to antidepressants. Use of pattern analysis. Archives of General Psychiatry 1984; 41:782-786. (Pubitemid 14092257)
12. Muthén B, Brown CH, Masyn K, Jo B, Khoo ST, Yang CC, Wang CP, Kellam S, Carlin J, Liao J. General growth mixture modeling for randomized preventive interventions. Biostatistics 2002; 3:459-475. (Pubitemid 35431224)
13. Muthén B, Asparouhov T. Growth mixture modeling: analysis with non-Gaussian random effects. In Longitudinal Data Analysis, Fitzmaurice G, Davidian M, Verbeke G, Molenberghs G (eds). Chapman & Hall/CRC Press: Boca Raton, FL, 2008; 143-165.
14. Rubin DB. Direct and indirect causal effects via potential outcomes. Scandinavian Journal of Statistics 2004; 31:161-170.
15. Mealli F, Imbens GW, Ferro S, Biggeri A. Analyzing a randomized trial on breast self-examination with noncompliance and missing outcomes. Biostatistics 2004; 5:207-222. (Pubitemid 41180224)
16. Gallop R, Small DS, Lin JY, Elliott MR, Joffe M, Ten Have TR. Mediation analysis with principal stratification. Statistics in Medicine 2009; 28:1108-1130.
17. McLachlan GJ, Peel D. Finite Mixture Models. Wiley: New York, 2000.
18. Titterington DM, Smith AFM, Makov UE. Statistical Analysis of Finite Mixture Distributions. Wiley: New York, 1985.
19. Muthén B, Shedden K. Finite mixture modeling with mixture outcomes using the EM algorithm. Biometrics 1999; 55:463-469. (Pubitemid 29302570)
20. Lin H, Turnbull BW, McCulloch CE, Slate E. Latent class models for joint analysis of longitudinal biomarker and event process data: application to longitudinal prostate-specific antigen readings and prostate cancer. Journal of the American Statistical Association 2002; 97:53-65.
21. Elliott MR, Gallo JJ, Ten Have TR, Bogner HR, Katz IR. Using a Bayesian latent growth curve model to identify trajectories of positive affect and negative events following myocardial infarction. Biostatistics 2005; 6:119-143.
22. Beunckens C, Molenberghs G, Verbeke G, Mallinckrodt C. A latent-class mixture model for incomplete longitudinal Gaussian data. Biometrics 2008; 64:96-105. (Pubitemid 351316868)
23. Muthén B, Muthén L. Mplus User's Guide. Muthén and Muthén: Los Angeles, CA, 2008.
24. Schwarz G. Estimating the dimension of a model. The Annals of Statistics 1978; 6:461-464.
25. Kass RE, Raftery AE. Bayes factors. Journal of the American Statistical Association 1993; 90:773-795.
26. Nylund KL, Asparouhov T, Muthén B. Deciding on the number of classes in latent class analysis and growth mixture modeling. A Monte Carlo simulation study. Structural Equation Modeling 2007; 14:535-569.
27. Ramaswamy V, DeSarbo W, Reibstein D, Robinson W. An empirical pooling approach for estimating marketing mix elasticities with PIMS data. Marketing Science 1993; 12:103-124.
28. Tarpey T, Petkova E, Ogden T. Profiling placebo responders by self-consistent partitioning of functional data. Journal of the American Statistical Association 2003; 98:850-858. (Pubitemid 38213974)
29. Tarpey T, Petkova E, Govindarajulu U. Predicting potential placebo effect in drug treated subjects. The International Journal of Biostatistics 2009; 5. DOI: 10.2202/1557-4679.1152.
30. Xu W, Hedeker D. A random-effects mixture model for classifying treatment response in longitudinal clinical trials. Journal of Biopharmaceutical Statistics 2001; 11:253-273. (Pubitemid 34532645)